In Vitro Modeling of Drug-Drug Interactions

  • Grant T. Generaux
Part of the Infectious Disease book series (ID)


In vitro modeling of drug-drug interactions (DDI) has tremendous potential to impact the prediction and management of DDIs during the development of new anti-infective agents positively. In this chapter, two fundamental types of in vitro models used for predicting and managing DDIs are introduced and discussed. The first type, referred to as static DDI models, produces a steady-state prediction of compound exposure change upon coadministration with a perpetrator of DDI. The second type of in vitro DDI model, the physiologically based pharmacokinetic (PBPK) model, combines in vitro data with a physiological representation of organs and blood flows and can provide a dynamic prediction of more complex DDI involving transporter/enzyme interplay and the effect of disease pathophysiology. The science of in vitro-in vivo extrapolation (IVIVE) for transporters, transporter/enzyme interplay, and special populations/diseases is currently developing at a rapid pace; however, in vitro modeling of DDI is already a scientifically mature subject with increasing regulatory acceptance and is evolving into a key asset to help in the development of life-altering medicines for patients in need.


  1. 1.
    Rodgers T, Leahy D, Rowland M (2005) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259–1276CrossRefGoogle Scholar
  2. 2.
    Rodgers T, Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238–1257CrossRefGoogle Scholar
  3. 3.
    Ito K, Iwatsubo T, Kanamitsu S et al (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50(3):387–411PubMedGoogle Scholar
  4. 4.
    Galetin A, Hinton LK, Burt H et al (2007) Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 8(7):685–693CrossRefGoogle Scholar
  5. 5.
    Oglive BW, Usuki E, Yerino P et al (2008) In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs (reaction phenotyping) with emphasis a cytochrome P450. Drug-Drug Interactions, 2nd edition 231–358Google Scholar
  6. 6.
    Zamek-Gliszczynski MJ, Lee CA, Poirier A et al (2013) ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clin Pharmacol Ther 94(1):64–79CrossRefGoogle Scholar
  7. 7.
    Jacobson TA (2004) Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94(9):1140–1146CrossRefGoogle Scholar
  8. 8.
    Maeda K, Ikeda Y, Fujita T et al (2011) Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 90(4):575–581CrossRefGoogle Scholar
  9. 9.
    Shardlow CE, Generaux GT, MacLauchlin CC et al (2011) Utilizing drug-drug interaction prediction tools during drug development: enhanced decision making based on clinical risk. Drug Metab Displays 39:2076–2084CrossRefGoogle Scholar
  10. 10.
    Fahmi OA, Maurer TS, Kish M et al (2008) A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Displays 36:1698–1708CrossRefGoogle Scholar
  11. 11.
    Rowland M, Lesko LJ, Rostami-Hodjegan A (2015) Physiologically based pharmacokinetics is impacting drug development and regulatory decision making. CPT Pharmacometrics Syst Pharmacol 4:313–315CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.New HopeUSA

Personalised recommendations